STAAR Surgical (NASDAQ:STAA) Shares Sold by Bridgewater Associates LP

Bridgewater Associates LP reduced its position in STAAR Surgical (NASDAQ:STAA) by 51.6% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 19,281 shares of the medical instruments supplier’s stock after selling 20,559 shares during the quarter. Bridgewater Associates LP’s holdings in STAAR Surgical were worth $716,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. FMR LLC lifted its holdings in shares of STAAR Surgical by 79.3% in the 3rd quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier’s stock valued at $263,000 after buying an additional 3,136 shares during the period. Larson Financial Group LLC raised its position in STAAR Surgical by 78.3% in the third quarter. Larson Financial Group LLC now owns 4,863 shares of the medical instruments supplier’s stock worth $181,000 after acquiring an additional 2,135 shares in the last quarter. Intech Investment Management LLC acquired a new stake in shares of STAAR Surgical in the third quarter valued at about $463,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of STAAR Surgical by 323.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 30,014 shares of the medical instruments supplier’s stock valued at $1,115,000 after acquiring an additional 22,925 shares during the period. Finally, LMR Partners LLP boosted its position in STAAR Surgical by 2.2% during the third quarter. LMR Partners LLP now owns 34,712 shares of the medical instruments supplier’s stock worth $1,290,000 after purchasing an additional 743 shares in the last quarter. Hedge funds and other institutional investors own 96.70% of the company’s stock.

STAAR Surgical Trading Down 4.7 %

NASDAQ:STAA opened at $27.72 on Tuesday. The firm has a market capitalization of $1.37 billion, a PE ratio of 63.00 and a beta of 0.61. STAAR Surgical has a 52 week low of $25.88 and a 52 week high of $52.68. The stock has a 50 day moving average of $30.58 and a 200-day moving average of $36.06.

Analyst Ratings Changes

Several brokerages have issued reports on STAA. Stifel Nicolaus reduced their price target on shares of STAAR Surgical from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Monday, August 26th. Canaccord Genuity Group reduced their target price on STAAR Surgical from $41.00 to $31.00 and set a “hold” rating on the stock in a research note on Friday, November 1st. Finally, Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $43.33.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.